| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Review
University of Colorado Denver, Aurora, Colorado
Submitted 1 July 2009 ; accepted in final form 4 September 2009
At present, six groups of chronic pulmonary hypertension (PH) are described. Among these, group 1 (and 1') comprises a group of diverse diseases termed pulmonary arterial hypertension (PAH) that have several pathophysiological, histological, and prognostic features in common. PAH is a particularly severe and progressive form of PH that frequently leads to right heart failure and premature death. The diagnosis of PAH must include a series of defined clinical parameters, which extend beyond mere elevations in pulmonary arterial pressures and include precapillary PH, pulmonary hypertensive arteriopathy (usually with plexiform lesions), slow clinical onset (months or years), and a chronic time course (years) characterized by progressive deterioration. What appears to distinguish PAH from other forms of PH is the severity of the arteriopathy observed, the defining characteristic of which is "plexogenic arteriopathy." The pathogenesis of this arteriopathy remains unclear despite intense investigation in a variety of animal model systems. The most commonly used animal models ("classic" models) are rodents exposed to either hypoxia or monocrotaline. Newer models, which involve modification of classic approaches, have been developed that exhibit more severe PH and vascular lesions, which include neointimal proliferation and occlusion of small vessels. In addition, genetically manipulated mice have been generated that have provided insight into the role of specific molecules in the pulmonary hypertensive process. Unfortunately, at present, there is no perfect preclinical model that completely recapitulates human PAH. All models, however, have provided and will continue to provide invaluable insight into the numerous pathways that contribute to the development and maintenance of PH. Use of both classic and newly developed animal models will allow continued rigorous testing of new hypotheses regarding pathogenesis and treatment. This review highlights progress that has been made in animal modeling of this important human condition.
bone morphogenetic protein; hypoxia; inflammation; progenitor cells
This article has been cited by other articles:
|
|
 |
|
  D. Urboniene, I. Haber, Y.-H. Fang, T. Thenappan, and S. L. Archer Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2010; 299(3): L401 - L412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sutendra, S. Bonnet, G. Rochefort, A. Haromy, K. D. Folmes, G. D. Lopaschuk, J. R. B. Dyck, and E. D. Michelakis Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension Science Translational Medicine, August 11, 2010; 2(44): 44ra58 - 44ra58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abe, M. Toba, A. Alzoubi, M. Ito, K. A. Fagan, C. D. Cool, N. F. Voelkel, I. F. McMurtry, and M. Oka Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension Circulation, June 29, 2010; 121(25): 2747 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Firth, J. Mandel, and J. X. J. Yuan Idiopathic pulmonary arterial hypertension Dis. Model. Mech., May 1, 2010; 3(5-6): 268 - 273. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
